Tenaya Q3 net loss $29.1M; first patient dosed in TN-201 HCM trial

Tenaya Therapeutics, Inc.

2023-Q3 EPS reported -$1.28

Q3 net loss $29.1M ($0.39/share); R&D $23.1M, G&A $7.8M; cash $128.1M into H1 2025.
First patient dosed in MyPeak-1 Phase 1b trial of TN-201 for MYBPC3-associated HCM.
FDA cleared TN-401 IND for PKP2-ARVC and granted Fast Track designation in Nov 2023.
Positive Phase 1 data for TN-301 (HDAC6 inhibitor) in HFpEF presented at HFSA 2023.
EMA granted Orphan Medicinal Product designation for TN-401 in Sep 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tenaya Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income $29.1 million, or $0.39 per share, EPS $0.39 per share.

Period: the third quarter ended September 30, 2023
Net income: $29.1 million, or $0.39 per share
EPS: $0.39 per share
Result: reported results

Exact text from the filing

Net loss for the quarter ended September 30, 2023, was $29.1 million, or $0.39 per share.

View on SEC.gov

Browse all earnings releases →

Tenaya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-061123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.